FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner.
Phillip M PiferLiangpeng YangManish KumarTongxin XieMitchell J FrederickAndrew HefnerBeth M BeadleDavid P MolkentineJessica M MolkentineAnnika DhawanMohamed AbdelhakiemAbdullah A OsmanBrian J LeibowitzJeffrey N MyersCurtis R PickeringVlad C SandulacheJohn Victor HeymachHeath D SkinnerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
FAK may represent a targetable therapeutic sensitizer linked to a known genomic marker of resistance.